Om Megashree Pharmaceuticals IPO Result Allotment Details

HomeBlogsIPO News

Om Megashree Pharmaceuticals IPO Result Allotment Details

Om Megashree Pharmaceuticals IPO result will be published tomorrow 12th Chaitra, 2081 (Tuesday). The allotment process will be held at the premises of the issue manager, Prabhu Capital Limited, in Lazimpat, Kathmandu. This is the second phase of IPO for the general public in Nepal before this the first phase of its IPO distribution was opened for the Nepalese working abroad. The IPO price per unit is set at Rs. 100 per share.

IPO Allocation Breakdown

  • Total Issued Capital: Rs. 60 Crores.
  • Public Issue: 30% (18,00,000 units worth Rs. 18 Crores).
    • Nepalese Citizens Working Abroad: 10% (1,80,000 units).
    • Mutual Funds: 5% (90,000 units).
    • Company Employees: 3% (54,000 units).
    • General Public: 14,76,000 units.

Key Highlights of the IPO Allotment

Particulars Details
Allotment Date 12th Chaitra, 2081
Issue Manager Prabhu Capital Limited, Lazimpat
Total Units for General Public 1,476,000 units
Par Value per Share NPR 100
Units Applied For 23,691,510 units
Total Capital Applied NPR 2.36 Arba
Total Applicants 1,988,836
Lucky Applicants 147,600
CARE Ratings CARE-NP BB- (Is) – Indicates moderate default risk

CARE Ratings Nepal’s Reaffirmation

CARE Ratings Nepal Limited (CRNL) has reaffirmed the following ratings for OMPL:

  • Issuer Rating: ‘CARE-NP BB- (Is)’ – indicating a moderate risk of default in meeting financial obligations.
  • Long-term Bank Facilities: ‘CARE-NP BB-’.
  • Short-term Bank Facilities: ‘CARE-NP A4’.

These ratings reflect the company’s financial stability and operational capabilities.

About Om Megashree Pharmaceuticals Limited

Om Megashree Pharmaceuticals is a Public  Company established on June 12, 2016. Engaged in manufacturing pharmaceutical products at our plant in Jugedi, Chitwan. With partial operations starting on February 19, 2024, our head office is located in New Baneshwor, Kathmandu. We aim to become a global name in pharmaceuticals by delivering high-quality, innovative, and affordable medicines, guided by our core values of integrity, innovation, quality, collaboration, growth, and unity.